BeOne Medicines: all 190 studies

Page 2 of 2. Open to participants first (46), then studies with results posted, then the rest; newest registration first within each.

• A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03430843Phase 3Results posted
• Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric CancerCompletedNCT03427814Phase 2Results posted
• Study of BGB-A317 in Participants With Previously Treated Unresectable HCCCompletedNCT03419897Phase 2Results posted
• A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT03412773Phase 3Results posted
• Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid TumorsTerminatedNCT03379259Phase 1/2Results posted
• Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT03358875Phase 3Results posted
• A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLLActive, not recruitingNCT03336333Phase 3Results posted
• Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid TumorsCompletedNCT03333915Phase 1/2Results posted
• Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)CompletedNCT03332173Phase 2Results posted
• A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular LymphomaCompletedNCT03332017Phase 2Results posted
• A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin LymphomaCompletedNCT03209973Phase 2Results posted
• Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)CompletedNCT03206970Phase 2Results posted
• Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT03206918Phase 2Results posted
• A Study to Investigate Zanubrutinib in Chinese Participants With B-cell LymphomaCompletedNCT03189524Phase 1Results posted
• A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent GlioblastomaCompletedNCT03150862Phase 1/2Results posted
• Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid TumorsCompletedNCT03150810Phase 1Results posted
• Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell LymphomaCompletedNCT03145064Phase 2Results posted
• A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)CompletedNCT03053440Phase 3Results posted
• Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell MalignanciesCompletedNCT02795182Phase 1Results posted
• The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid TumorsCompletedNCT02660034Phase 1Results posted
• BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid MalignanciesCompletedNCT02569476Phase 1Results posted
• Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced TumorsCompletedNCT02407990Phase 1Results posted
• Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid MalignanciesCompletedNCT02343120Phase 1/2Results posted
• A Study to Investigate the Relative Bioavailability and Food Effect of Tablet for Oral Suspension of Sonrotoclax in Healthy AdultsCompletedNCT07628881Phase 1
• A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström MacroglobulinemiaActive, not recruitingNCT07169331Phase 4
• A Study to Investigate the Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332) in Healthy AdultsCompletedNCT07141511Phase 1
• A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid ArthritisTerminatedNCT07100938Phase 2
• A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) InhibitorsActive, not recruitingNCT06970743Phase 3
• Effect of Phenytoin or Itraconazole on How BGB-16673 is Absorbed and Removed From the Body in Healthy ParticipantsCompletedNCT06906809Phase 1
• A Study of How [14C]-BGB-16673 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy ParticipantsCompletedNCT06776679Phase 1
• A Study of Different Forms of BGB-43395 and Food Effect in Healthy ParticipantsCompletedNCT06761898Phase 1
• A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung CancerTerminatedNCT06685718Phase 1
• A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic LeukemiaActive, not recruitingNCT06637501Phase 2
• A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or AmplificationTerminatedNCT06585488Phase 1
• An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid TumorsTerminatedNCT06568614Phase 1
• A Study to Evaluate the Effects of Phenytoin and Itraconazole on Sonrotoclax (BGB-11417) in Healthy VolunteersCompletedNCT06543043Phase 1
• A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid TumorsTerminatedNCT06540066Phase 1
• A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid TumorsTerminatedNCT06487858Phase 1
• A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid TumorsCompletedNCT06422520Phase 1
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological DiseasesCompletedNCT06342713Phase 1
• A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage TumorsActive, not recruitingNCT06257264Phase 1
• BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid TumorsCompletedNCT06253195Phase 1
• Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung CancerCompletedNCT06091943Phase 1
• Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)Active, not recruitingNCT06073821Phase 3
• A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT06010303Phase 2
• A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström MacroglobulinemiaActive, not recruitingNCT05952037Phase 2
• BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid TumorsTerminatedNCT05935098Phase 1
• A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid TumorsTerminatedNCT05904496Phase 1
• A Study to Investigate the Absorption, Metabolism and Excretion of [14C]-BGB-11417CompletedNCT05844111Phase 1
• A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell MalignanciesTerminatedNCT05828589Phase 1
• Bioequivalence of a Zanubrutinib Tablet Compared to Capsules in Healthy Adult ParticipantsCompletedNCT05767398Phase 1
• A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous NephropathyActive, not recruitingNCT05707377Phase 2/3
• A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.Active, not recruitingNCT05661955Phase 1/2
• Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese ParticipantsWithdrawnNCT05644626Phase 1
• A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung CancerActive, not recruitingNCT05635708Phase 2
• Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular CarcinomaWithdrawnNCT05564338Phase 3
• Relative Bioavailability of Zanubrutinib Tablets Compared to Capsules and Effects of Food on the Pharmacokinetics of the Tablet in Healthy AdultsCompletedNCT05547399Phase 1
• Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid TumorsTerminatedNCT05494762Phase 1
• Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingNCT05479994Phase 2
• Safety, Tolerability, and Pharmacokinetics of BGB-23339 in Healthy Japanese and Caucasian SubjectsWithdrawnNCT05387668Phase 1
• A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid TumorsTerminatedNCT05381909Phase 1
• A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone LymphomaActive, not recruitingNCT05100862Phase 3
• First-in-Human, Single- and Multiple-Ascending Dose and Food-Effect Study of BGB-23339 in Healthy ParticipantsCompletedNCT05093270Phase 1
• Study of BGB-11417 in Adult Participants With Mature B-cell MalignanciesCompletedNCT04883957Phase 1
• BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid TumorsCompletedNCT04649385Phase 1
• Zanubrutinib in Participants With Active Proliferative Lupus NephritisCompletedNCT04643470Phase 2
• Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin LymphomaTerminatedNCT04486391Phase 3
• Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT04379635Phase 3
• Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell MalignanciesActive, not recruitingNCT04277637Phase 1
• Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid TumorsCompletedNCT04215978Phase 1
• Study of Zanubrutinib in Japanese Participants With B-Cell MalignanciesCompletedNCT04172246Phase 1/2
• A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of ZanubrutinibActive, not recruitingNCT04170283Phase 3
• Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced MalignanciesCompletedNCT04164199Phase 3
• Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-BGB-3111 in Healthy MalesCompletedNCT04163783Phase 1
• Study to Evaluate the Effect of Food on the Pharmacokinetics of a BGB-3111 in Healthy SubjectsCompletedNCT04163523Phase 1
• Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) TreatmentCompletedNCT04116437Phase 2
• A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell MalignanciesNo longer availableNCT04052854
• A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell TransplantationActive, not recruitingNCT04002297Phase 3
• Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial CarcinomaActive, not recruitingNCT03967977Phase 3
• Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid TumorsCompletedNCT03905148Phase 1
• The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid TumorCompletedNCT03641586Phase 1
• A Pharmacokinetic Study to Assess Drug-drug Interaction Between Zanubrutinib and a Cocktail of Substrates in Healthy SubjectsCompletedNCT03561298Phase 1
• Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian CancerActive, not recruitingNCT03519230Phase 3
• BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction CarcinomaCompletedNCT03469557Phase 2
• Safety and Pharmacokinetics of Zanubrutinib (BGB-3111) in Healthy Subjects and Those With Impaired Liver FunctionCompletedNCT03465059Phase 1
• A Two-Part Phase 1 Study to Investigate the Safety and Tolerability of Supratherapeutic Dose of Zanubrutinib and Effect of Zanubrutinib on Cardiac Repolarization in Healthy SubjectsCompletedNCT03432884Phase 1
• Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung CancerCompletedNCT03432598Phase 2
• Phase 1 Study to Investigate Effect of Rifampin and Itraconazole on the Pharmacokinetics of BGB-3111 in Healthy SubjectsCompletedNCT03301181Phase 1
• Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid TumorsCompletedNCT02610361Phase 1
• Phase 1a/1b BGB-290 for Advanced Solid Tumors.CompletedNCT02361723Phase 1

← BeOne Medicines overview and focus areas